TCGA-ZF-A9R3-01A-11R-A38B-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 31.1760841
- os_event
- true
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.530
- INTERFERON_GAMMA_RESPONSE+0.330
- BILE_ACID_METABOLISM+0.300
- PROTEIN_SECRETION+0.250
- P53_PATHWAY+0.160
- ANDROGEN_RESPONSE+0.150
- FATTY_ACID_METABOLISM+0.140
- HEME_METABOLISM+0.140
- XENOBIOTIC_METABOLISM+0.140
- ADIPOGENESIS+0.130
Top 10 suppressed
- E2F_TARGETS-0.500
- MYC_TARGETS_V1-0.490
- G2M_CHECKPOINT-0.440
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.430
- MYC_TARGETS_V2-0.410
- MITOTIC_SPINDLE-0.290
- APICAL_JUNCTION-0.250
- DNA_REPAIR-0.240
- COAGULATION-0.230
- PANCREAS_BETA_CELLS-0.230
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8518308 | — | F | 0.800 |
| 2 | 7c025d06-2593-493c-b4a5-9f976149b0e2 | — | — | 0.755 |
| 3 | 82988 | EPN | Supratentorial EPN | 0.752 |
| 4 | ERR2598274 | fetal | fetal | 0.748 |
| 5 | SRR1313122 | — | B | 0.747 |
| 6 | R342 | — | — | 0.744 |
| 7 | SRR12475148 | — | — | 0.727 |
| 8 | BS_A13BMEF5 | low-grade glioma | — | 0.722 |
| 9 | TCGA-OR-A5LH-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.717 |
| 10 | C3L-02348 | — | cohortA1 | 0.714 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.530 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.330 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.300 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.250 | Remibrutinib | — uncovered |
| P53_PATHWAY | 0.160 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.150 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.140 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.140 | Temsirolimus | — uncovered |
| XENOBIOTIC_METABOLISM | 0.140 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.130 | Inavolisib | — uncovered |
| PEROXISOME | 0.110 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.090 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.070 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.060 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.060 | Inavolisib | — uncovered |
| APOPTOSIS | 0.020 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.020 | Remibrutinib | — uncovered |